Home › Companies › TECX

Tectonic Therapeutic

TECX Rare disease Lead: Phase 2 2 Biotech Distilled articles ↓

Cardiovascular Protein

Most recent annual filing: 2026-02-26

Pipeline (3 active programs)

TX45

Protein Target: RXFP1

Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction Phase 2 subcutaneous
Pulmonary Hypertension Associated with Interstitial Lung Disease Phase 2 subcutaneous

TX2100

Protein Target: APJ, APLNR

Hereditary Hemorrhagic Telangiectasia Phase 1 subcutaneous

Technology platforms

GEODe

GPCRs Engineered for Optimal Discovery — proprietary yeast display platform for discovering biologic drugs (antibodies, Fab, VHH) targeted to GPCRs; enables stabilization of pharmacologically relevant GPCR conformations for naïve antibody selection; focus areas include cardiovascular, fibrotic, and rare diseases

Biotech Distilled coverage (2)

2026-06-10 UPDATE: Tectonic Therapeutic (TECX) - The Clock is Set
2026-06-09 Tectonic Therapeutic (TECX) — Scientific Deep Dive for TX45 (Relaxin/RXFP1) and TX2100 (APJ Antagonist)

Articles open on Substack. Some deep dives are subscriber-only.